188 completed, 100 unknown, 31 terminated, 26 recruiting. 171 Phase 2, 133 Phase 3, 38 Phase 1, 30 Not applicable, 3 Early Phase 1.
Follow Chemotherapy, Adjuvant: new trials by email Literature Review of Chemotherapy, Adjuvant trials Research Report on Chemotherapy, Adjuvant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Perioperative Cemiplimab for Resectable Non-Small Cell Lung Cancer With High PD-L1 Cemiplimab, Adjuvant chemotherapy - Lung Cancer (NSCLC) | Phase 2 | Not yet recruiting | Henry Ford Health System | 33 | 2027-01-01 | 2026-07-15 |
| ctDNA-Guided Chemotherapy Omission With Ribociclib Plus Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer Aromatase inhibitor (± ovarian suppression) plus Ribociclib, 4 cycles of TC (docetaxel + cyclophosphamide) adjuvant chemotherapy - Breast Cancer | Phase 2 | Not yet recruiting | Fudan University | 388 | 2026-10-01 | 2026-02-20 |
| Adjuvant Trial in Pancreatic Neuroendocrine Tumors Adjuvant chemotherapy with Capecitabine-Temozolomide, Active surveillance - Pancreatic Neuroendocrine Tumors (pNET), Pancreatic Neuroendocrine Tumors | Phase 3 | Not yet recruiting | Gustave Roussy, Cancer Campus, Grand Paris | 300 | 2026-09-01 | 2026-05-15 |
| Dynamic Risk-adapted EBV-DNA and MRI-guided De-concurrent Chemotherapy in Nasopharyngeal Carcinoma Observation, Adjuvant therapy - Nasopharyngeal Carcinoma (NPC) | Phase 2 | Recruiting | Fudan University | 148 | 2026-08-01 | 2026-08-13 |
| Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma Adjuvant Therapy, Comprehensive Geriatric Assessment, Computed Tomography - Cutaneous Melanoma | Phase 3 | Recruiting | ECOG-ACRIN Cancer Research Group | 428 | 2026-04-17 | 2026-09-24 |
| Neoadjuvant CAPEOX Versus Upfront Surgery for Locally Advanced Colon Cancer With Elevated CEA: A Single-Center, Open-Label, Randomized Controlled Trial ctDNA-Based Molecular Residual Disease (MRD) Monitoring and Immunoscore Assessment, Neoadjuvant Chemotherapy, Adjuvant chemotherapy - Minimal Residual Disease, Immunoscore | Not applicable | Not yet recruiting | Sun Yat-sen University | 100 | 2026-02-24 | 2026-02-17 |
| ctDNA-Based Adjuvant Chemotherapy for High-Risk Rectal Cancer Adjuvant chemotherapy - Rectal Cancer | Phase 3 | Recruiting | Erasmus Medical Center | 103 | 2025-10-14 | 2026-10-02 |
| Neoadjuvant Pembrolizumab With a Watch-and-wait Strategy for dMMR/MSI-H Localized Colon Cancer: PREMICES Study. Pembrolizumab Injection [Keytruda], Watch-and-wait approach, Surgery - Colon Cancer | Phase 2 | Not yet recruiting | GERCOR - Multidisciplinary Oncology Cooperative Group | 60 | 2025-09-01 | 2025-06-13 |
| Tislelizumab Combined With Anlotinib and Nab-paclitaxel in II-III Resectable Non-small Cell Lung Cancer : A Prospective, Single-Arm, Phase II Study neoadjuvant therapy, Surgery, Adjuvant therapy - NSCLC, Tislelizumab | Phase 2 | Recruiting | Qilu Hospital of Shandong University | 34 | 2025-07-25 | 2026-10-13 |
| Impact of Omitting Chemo Based on Patient's Selection for ER-Positive, HER2-Negative Breast Cancer With Ribociclib and Endocrine Therapy Ribociclib 400mg, Letrozole 2.5mg, Anastrazole 1mg - HER2 Negative Breast Cancer | Phase 2 | Recruiting | Yale University | 140 | 2025-07-09 | 2026-05-26 |
| Neoadjuvant SBRT Followed by Nab-Paclitaxel Combined With Toripalimab in HR+/HER2- Breast Cancer Stereotactic Body Radiation Therapy (SBRT), Toripalimab, Neoadjuvant Chemotherapy - Breast Cancer | Phase 2 | Recruiting | Xijing Hospital | 27 | 2025-06-05 | 2026-08-14 |
| Chemotherapy Omission in HR-positive/HER2-negative Breast Cancer With Lymph Node Negative Disease Receiving Adjuvant Endocrine Therapy and CDK4/6 Inhibitor 4 cycles of TC (docetaxel + cyclophosphamide) adjuvant chemotherapy, aromatase inhibitor (± ovarian suppression) plus CDK4/6 inhibitor - Breast Cancer | Phase 3 | Not yet recruiting | Fudan University | 2508 | 2025-06-02 | 2025-05-30 |
| OPTImaL:Optimisation of Treatment for Patients With Low Stage Triple-negative Breast Cancer With High Stromal Tumor-infiltrating Lymphocytes Adjuvant chemotherapy, No adjuvant chemotherapy - Breast Cancer Stage I, Triple Negative Breast Cancer (TNBC) | Recruiting | The Netherlands Cancer Institute | 490 | 2025-04-15 | 2025-04-23 | |
| Randomized Phase II Trial Evaluating DFS in The Absence of an Adjuvant Component of Perioperative Chemotherapy in Patients With Gastric Cancer Surveillance, Adjuvant Chemotherapy - Gastric Cancer | Phase 2 | Not yet recruiting | Nizhny Novgorod Regional Clinical Oncology Center | 228 | 2025-04-15 | 2025-04-24 |
| Adjuvant PD-1 Blockade for High-risk Stage-II DMMR/MSI-H Colorectal Cancer Tislelizumab, Adjuvant chemotherapy - Colorectal Cancer, Microsatellite Instability High | Phase 3 | Recruiting | Sun Yat-sen University | 180 | 2024-11-01 | 2024-11-07 |
| Tislelizumab Combined With Capecitabine for Nasopharyngeal Carcinoma With Residual EBV DNA After Radiotherapy Adjuvant therapy - Nasopharyngeal Cancinoma (NPC) | Phase 2 | Recruiting | Fudan University | 76 | 2024-09-14 | 2025-07-16 |
| Adjuvant Chemoradiotherapy Versus Chemotherapy for Pancreatic Cancer (ADJUPANC) Adjuvant chemoradiotherapy, Adjuvant chemotherapy - Pancreatic Cancer | Phase 3 | Recruiting | Changhai Hospital | 770 | 2024-08-06 | 2025-02-04 |
| ctDNA-guided Selection of Adjuvant Chemotherapy Regimens for Elderly Colon Cancer Patients After Surgery: A Single-center, Randomized, Controlled Study 6-month adjuvant chemotherapy with 5-FU monotherapy, XELOX intensive treatment group - Colon Cancer, Colon Cancer (Stage II &Amp;Amp;Amp; III) | Phase 3 | Recruiting | Zhejiang Cancer Hospital | 312 | 2024-07-03 | 2024-09-24 |
| Efficacy and Safety of Conventional Neoadjuvant Therapy Versus Total Neoadjuvant Therapy in Older Patients With Locally Advanced Rectal Cancer Short course radiotherapy, Adjuvant chemotherapy (optional), Total mesorectal excision - Locally Advanced Rectal Cancer, Older People | Not applicable | Recruiting | Jules Bordet Institute | 230 | 2024-02-07 | 2026-08-03 |
| Prognostic Factors for Survival in Patients With Cholangiocarcinoma Resection/Ablation of tumor, Palliative chemotherapy, Neoadjuvant chemotherapy - Cholangiocarcinoma | Unknown | Copenhagen University Hospital, Rigshospitalet | 2000 | 2024-02-01 | 2024-04-17 |
Showing 20 of 384. Sign in to see all of them.
Breast Neoplasms (74) · Colorectal Neoplasms (40) · Central Nervous System Neoplasms (37) · Colonic Neoplasms (36) · Rectal Neoplasms (34) · Glioblastoma (23) · Carcinoma, Non-Small-Cell Lung (21) · Gliosarcoma (20) · Lung Neoplasms (18) · Stomach Neoplasms (17) · Head and Neck Neoplasms (16) · Pancreatic Neoplasms (16) · Ovarian Neoplasms (14) · Sarcoma (14) · Squamous Cell Carcinoma of Head and Neck (13)
European Organisation for Research and Treatment of Cancer - EORTC (22) · Children's Cancer and Leukaemia Group (12) · National Cancer Institute (NCI) (11) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (11) · Memorial Sloan Kettering Cancer Center (10) · Case Comprehensive Cancer Center (9) · Mayo Clinic (8) · UNICANCER (8) · Institute of Cancer Research, United Kingdom (7) · Sun Yat-sen University (7) · Children's Oncology Group (6) · City of Hope Medical Center (6) · Fudan University (6) · Radiation Therapy Oncology Group (6) · Roswell Park Cancer Institute (6)
United States (139) · United Kingdom (68) · China (52) · France (47) · Italy (30) · Netherlands (30) · Germany (28) · Belgium (27) · Switzerland (23) · Canada (20) · Spain (20) · Australia (14) · Ireland (13) · Japan (12) · Austria (11)
Edward F. McClay, MD (3) · Larry Kleinberg, MD (3) · Laurent Bedenne, MD (3) · Vered Stearns, MD (3) · William W. Wong, MD (3) · Aaron H. Wolfson, MD (2) · Alexander M. M. Eggermont, MD, PhD (2) · Ann Barrett (2) · Barbara L. Smith, MD, PhD (2) · Barry Pizer, MD (2) · Bernard Nordlinger, MD (2) · Daniel Rea, MD (2) · David Cunningham, MD (2) · David Ellison, MD (2) · David J. Adelstein, MD (2)
PMID 25592642, PMID 10394416, PMID 10615079, PMID 11286848, PMID 11762335, PMID 11813623, PMID 11835236, PMID 12573762, PMID 12749710, PMID 12957458, PMID 14673047, PMID 15667958, PMID 15821648, PMID 15867769, PMID 16399443, PMID 16524973, PMID 16680602, PMID 16791447, PMID 16868545, PMID 17013570, PMID 17030548, PMID 17240136, PMID 17401004, PMID 17554118, PMID 17607120, PMID 17652651, PMID 17698804, PMID 17705175, PMID 17822748, PMID 17878480, PMID 17971585, PMID 18083404, PMID 18191528, PMID 18358928, PMID 18372134, PMID 18403492, PMID 18477802, PMID 18506026, PMID 18509084, PMID 18620949, PMID 18650514, PMID 18797468, PMID 18801470, PMID 18952561, PMID 19070889, PMID 19218306, PMID 19231157, PMID 19269519, PMID 19269520, PMID 19273696
P30CA006973 (9), P30CA043703 (8), P30CA015083 (7), P30CA033572 (6), U10CA032102 (4), 2005 (3), U01CA062475 (3), 2004 (2), P30CA008748 (2), P30CA036727 (2), U10CA027469 (2), 2008 (1), 2009 (1), 2014 (1), 2015 (1)